Company Presentation - AnaptysBio Inc's president and CEO Daniel Faga will present at the 43rd Annual J P Morgan Healthcare Conference on January 14 2025 at 4 30pm PT 7 30pm ET [1] - A live webcast of the presentation will be available on the investor section of the Anaptys website with a replay available for at least 30 days following the event [2] Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases [3] - The company's lead program rosnilimab is in Phase 2b trials for rheumatoid arthritis and Phase 2 trials for ulcerative colitis [3] - AnaptysBio's portfolio includes ANB033 in Phase 1 trials and ANB101 soon to enter clinical development [3] - The company has licensed multiple therapeutic antibodies to GSK including an anti-PD-1 antagonist and an anti-TIM-3 antagonist [3] Contact Information - Nick Montemarano Senior Director of Investor Relations and Strategic Communications can be reached at 858 732 0178 or investors@anaptysbio com [4]

Shares of AnaptysBio, Inc. (ANAB) , a clinical-stage biotechnology company, plunged 32.8% on Dec. 11 after it announced that the phase IIb study of pipeline candidate, ANB032, a BTLA agonist, was unsuccessful.Consequently, ANAB discontinued any further investment in this asset.AnaptysBio has lost 27.6% so far this year compared with the industry’s decline of 8.1%.Image Source: Zacks Investment ResearchMore on ANAB’s Study FailureThe ARISE-AD study evaluated the efficacy, safety, tolerability, pharmacokineti ...

On Wednesday, AnaptysBio, Inc. ANAB announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema.“While ANB032 was safe and well tolerated, we’re disappointed by these efficacy results in AD and will discontinue further investment in this asset. Moving forward, our resources and capital will be focused on the rest of our exciting autoimmune por ...

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid arthritis in February 2025 for rosnilimab, a PD-1+ T cell depleter and agonistFunded beyond additional clinical data catalysts including Phase 2 data in ulcerative colitis for rosnilimab and Phase 1b data for ANB033 and ANB101Year-end 2024 cash of approximately $415 million and extending cash runway guidance through year-e ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. AnaptysBio, Inc. (ANAB) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.AnaptysBio, Inc. is a member of our Medical group, which includes 1022 different companies and currently sits at #3 in the Zacks Sector R ...

AnaptysBio, Inc. (ANAB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnings p ...

AnaptysBio, Inc. (ANAB) has been beaten down lately with too much selling pressure. While the stock has lost 32.8% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator ...

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to loss of $1.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.72%. A quarter ago, it was expected that this company would post a loss of $1.20 per share when it actually produced a loss of $1.71, delivering a surprise of -42.50%.Over the last four quarters, the company has surpas ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Emerging Growth Company ☐ FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37985 ANAPTYSBIO, INC. (Exact name of registrant as specified in its charter) Delaware 20-3828755 (State o ...

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update • Phase 1 trial initiated in healthy volunteers for ANB033, our anti-CD122 antagonist • Reiterating cash runway through year-end 2026 SAN DIEGO, Nov. 5, 2024 — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended Sept. 30, 2024 and provided a business update. "We remain confident in the po ...